



**Alternative TLR2 agonists bound to naïve CD4<sup>+</sup> T cells enhance T<sub>h1</sub> development.** Naïve B6 CD4<sup>+</sup> T cells (N=3/group) were co-incubated with saline vehicle or 10 mg/ml of Pam<sub>3</sub>Cys<sub>4</sub>, Pam<sub>2</sub>Cys<sub>4</sub> or FSL-1 for 3 hours at 37 °C, washed 3 times and stimulated with plate bound CD3e and CD28 Abs under T<sub>h1</sub> polarizing conditions for 96 hours and stained for intracellular IFN-γ expression. The results shown are a representative result of 2 independent experiments expressed as the mean percent abundance of IFN-γ<sup>+</sup> cells ± S.D.




**Naïve OT2 and OT2<sup>Pam3</sup> cells preferentially traffic to tumor draining lymph nodes.** Hosts with established EG.7-OVA tumors received  $10^6$  naïve CD45.1<sup>+</sup> OT2, OT2<sup>Pam3</sup> or B6 cells and tumor draining lymph nodes (TDLN) and right flank derived (non-tumor draining) lymph nodes (NDLN) were assessed for the percent abundance of CD45.1<sup>+</sup> CD4<sup>+</sup> T cells 36 hours after adoptive transfer. Shown is a representative result from pooled lymph nodes (n=4/group) from 3 independent experiments.

A.




B.



### Tumor-infiltrating OT2<sup>Pam3</sup> and host TDLN CD8<sup>+</sup> T cells express IFN- $\gamma$ .

(A) A representative FACS plots from at least three independent experiments showing the percent abundance of tumor infiltrating CD45.1<sup>+</sup> IFN- $\gamma$ <sup>+</sup> and CD45.1<sup>+</sup> IL-17A<sup>+</sup> cells twelve days after saline injection or adoptive transfer of indicated CD45.1<sup>+</sup> CD4<sup>+</sup> T cells.

(B) TDLN (n=6/group) isolated from hosts treated with indicated CD4<sup>+</sup> T cells were analyzed for the percent abundance of IFN- $\gamma$ <sup>+</sup> CD8<sup>+</sup> T cells. Shown is a representative result of indicated pooled lymph nodes from at least three independent experiments.



**PD-L1 blockade enhances IFN- $\gamma$  production from tumor-infiltrating OT2<sup>Pam3</sup> cells.** Infiltrating CD45.1<sup>+</sup> cells from tumors in recipients (N  $\geq$  4/group; p<sup>\*\*</sup> < 0.01) isolated 10 days after treatment were stimulated with 1.0  $\mu$ g/ml plate bound CD3 $\epsilon$  Abs for 72 hours and assessed for IFN- $\gamma$  production by ELISA. Data shown is a representative result from 2 independent experiments depicting IFN- $\gamma$  production from 10<sup>5</sup> CD45.1<sup>+</sup> cells.